What is Tesamorelin studied for in research?

In laboratory and preclinical research, Tesamorelin is studied as a GHRH analog for its effects on growth hormone secretion, the somatotropic axis, and lipid metabolism. It is for research use only and is not approved for human use.

Is Tesamorelin the same as GHRH?

Tesamorelin is a synthetic analog of GHRH with structural modifications that improve stability. It acts on the same GHRH receptor pathway that native GHRH does, which is why it is used as a research tool for that pathway.

COMPOUND GUIDE 5 MIN READ

Tesamorelin: Research Overview and Mechanism

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) studied in laboratory and preclinical research for its effects on the somatotropic axis, growth hormone secretion dynamics, and lipid metabolism. It is supplied as lyophilized powder for laboratory research only and is not for human use in this form. This overview describes how the GHRH analog is characterized in the research literature, including its public regulatory record as Egrifta, and not a therapeutic effect of the material sold here.

What Tesamorelin is

Tesamorelin is a stabilized synthetic analog of growth hormone-releasing hormone (GHRH). Structural modifications improve its stability relative to native GHRH, making it a useful tool compound for studying the GHRH receptor and downstream growth hormone signaling in research models.

Pathways it is studied within

In research, Tesamorelin is used to investigate GHRH receptor activity, pulsatile growth hormone secretion, IGF-1 signaling, and lipid-metabolism endpoints such as visceral adiposity in preclinical models.

As a molecule, tesamorelin also has a public regulatory record: it is approved under the brand name Egrifta. That is a verifiable fact about the compound, stated here as regulatory context only. It does not change the status of this material, which is supplied strictly for in-vitro laboratory research and is not for human use.

Handling and documentation

Pinnacle Tesamorelin ships as a lyophilized powder built on the stabilized GHRH(1-44) analog structure (molecular weight near 5135.9 g/mol), carrying the N-terminal trans-3-hexenoyl modification that distinguishes it from native GHRH. Store the sealed vial at -20°C protected from light, then reconstitute with bacteriostatic water directed against the inner wall rather than onto the pellet.

Once in solution, refrigerate and keep freeze-thaw cycles to a minimum, since the extended 44-residue chain is more prone to degradation than a short peptide. Every lot is third-party tested by HPLC and mass spectrometry and ships with a lot-matched Certificate of Analysis; our reconstitution and storage guide covers the handling detail.

All products are intended strictly for in-vitro laboratory research and development use only. Not for human or veterinary use, not a drug, food, or cosmetic, and not intended to diagnose, treat, cure, or prevent any disease.